Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab
T Kobayashi, K Ito, T Kojima, M Kato, S Kanda… - Cancer …, 2021 - Wiley Online Library
The use of immune checkpoint inhibitors to treat urothelial carcinoma (UC) is increasing
rapidly without clear guidance for validated risk stratification. This multicenter retrospective …
rapidly without clear guidance for validated risk stratification. This multicenter retrospective …
Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab.
T Kobayashi, K Ito, T Kojima, M Kato, S Kanda… - Cancer …, 2020 - europepmc.org
The use of immune checkpoint inhibitors to treat urothelial carcinoma (UC) is increasing
rapidly without clear guidance for validated risk stratification. This multicenter retrospective …
rapidly without clear guidance for validated risk stratification. This multicenter retrospective …
[HTML][HTML] Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab
T Kobayashi, K Ito, T Kojima, M Kato, S Kanda… - Cancer …, 2021 - ncbi.nlm.nih.gov
The use of immune checkpoint inhibitors to treat urothelial carcinoma (UC) is increasing
rapidly without clear guidance for validated risk stratification. This multicenter retrospective …
rapidly without clear guidance for validated risk stratification. This multicenter retrospective …
Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab
T Kobayashi, K Ito, T Kojima, M Kato, S Kanda… - Cancer …, 2021 - search.proquest.com
The use of immune checkpoint inhibitors to treat urothelial carcinoma (UC) is increasing
rapidly without clear guidance for validated risk stratification. This multicenter retrospective …
rapidly without clear guidance for validated risk stratification. This multicenter retrospective …
Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab
小林恭， 小川修 - Cancer Science, 2021 - cir.nii.ac.jp
抄録 The use of immune checkpoint inhibitors to treat urothelial carcinoma (UC) is
increasing rapidly without clear guidance for validated risk stratification. This multicenter …
increasing rapidly without clear guidance for validated risk stratification. This multicenter …
[PDF][PDF] Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab
T Kobayashi - 2020 - core.ac.uk
The use of immune checkpoint inhibitors to treat urothelial carcinoma (UC) is increasing
rapidly without clear guidance for validated risk stratification. This multicenter retrospective …
rapidly without clear guidance for validated risk stratification. This multicenter retrospective …
Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab
T Kobayashi, K Ito, T Kojima, M Kato… - Cancer …, 2021 - repository.kulib.kyoto-u.ac.jp
The use of immune checkpoint inhibitors to treat urothelial carcinoma (UC) is increasing
rapidly without clear guidance for validated risk stratification. This multicenter retrospective …
rapidly without clear guidance for validated risk stratification. This multicenter retrospective …
Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab
T Kobayashi, K Ito, T Kojima, M Kato… - Cancer …, 2021 - pubmed.ncbi.nlm.nih.gov
The use of immune checkpoint inhibitors to treat urothelial carcinoma (UC) is increasing
rapidly without clear guidance for validated risk stratification. This multicenter retrospective …
rapidly without clear guidance for validated risk stratification. This multicenter retrospective …
[引用][C] Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab
T Kobayashi, K Ito, T Kojima, M Kato, S Kanda… - Cancer Science, 2020 - cir.nii.ac.jp
Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated
with pembrolizumab | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …
with pembrolizumab | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …
Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab
T Kobayashi, K Ito, T Kojima, M Kato, S Kanda… - Cancer …, 2021 - search.proquest.com
The use of immune checkpoint inhibitors to treat urothelial carcinoma (UC) is increasing
rapidly without clear guidance for validated risk stratification. This multicenter retrospective …
rapidly without clear guidance for validated risk stratification. This multicenter retrospective …